Coordinator: Maria Luisa Nolli

Staff (qualification):

Alessandra Fucci (PhD)

Assunta Riccio (PhD)

Egildo Luca D’Andrea (PhD)

Research areas

The PF laboratory has a consolidated experience in production, purification and characterization of recombinant proteins and monoclonal antibodies.

PF activities also include the setup of immunological (ELISA) and enzymatic assays, the development of tech-transfer protocols for biosimilars’ industrialization, the manufacturing of recombinant enzymes (including Taq DNA polymerase and T7 RNA polymerase) and the labeling of protein and antibodies.

Technologies used and/or developed

The laboratory has at its disposal multiple bacterial strains and eukaryotic cell lines, as well as a large library of expression vectors for the production of recombinant proteins and antibodies. Lab effectiveness is ensured by the use of cutting-edge tools and methods, such as the High-Throughput Expression Screening for the rapid identification of optimal conditions of expression, the disposable bioreactors (0.1-20L) to adapt the production scale to clients’ needs, and the AKTAxpress FPLC purification system, capable of operating with several chromatographic columns simultaneously. Lastly, advanced analytical techniques, such as SPR and HPLC, together with the standard biochemical analyses, are used for proteins and antibodies’ characterization.

Services

Proteins and Recombinant Antibodies

- Cloning and expression of recombinant proteins in prokaryotic and/or eukaryotic systems;

- Cloning and expression of recombinant antibodies (rAb) in mammal cells

- Chimeric antibody production

- Production and purification of proteins and antibodies (from micrograms to gram)

- Biochemical and functional characterization of proteins and antibodies (HPLC, MS, SPR, DC)

Monoclonal Antibodies

• Imminization strategy design
• Antigen design and production
• Immunization (with recombinant proteins, peptides and/or cellular antigens)
• Serum antibody tritation
• Somatic fusion
• Primary screening of hybridomas
• Subcloning of hybridomas
• Secondary screening
• Stabilization of the hybridoma / s
• Generation of the cell bank
• Purification of the imAb(s) (from 10 to 100,000 ug)
• Characterization (isotype, epitope mapping, SDS-PAGE, WB, ELISA,HPLC, SPR)

PERSONALIZED ANALYTICAL AND IMMUNOENZYME TESTS

Product portfolio

• Biosimilars (recombinant clones, expression vectors, production and characterization protocols)

Insulin

Glargina

Interferon alpha

Interferon beta

• Recombinant proteins

PIN1

GDF15

IFNa

IFNb

• Recombinant Taq
• Mycoplasma detection kit